Clinical trial
Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
NCT04890353 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
- Lead sponsor
- Xuanwu Hospital, Beijing
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- December 1, 2021
- Completion date
- February 28, 2023
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute ischemic stroke